Verrica Pharmaceuticals (VRCA) EBIAT (2021 - 2025)
Verrica Pharmaceuticals (VRCA) has 5 years of EBIAT data on record, last reported at -$8.1 million in Q4 2025.
- For Q4 2025, EBIAT rose 50.17% year-over-year to -$8.1 million; the TTM value through Dec 2025 reached -$17.9 million, up 76.64%, while the annual FY2025 figure was -$17.9 million, 76.64% up from the prior year.
- EBIAT reached -$8.1 million in Q4 2025 per VRCA's latest filing, down from -$274000.0 in the prior quarter.
- Across five years, EBIAT topped out at $204000.0 in Q2 2025 and bottomed at -$24.8 million in Q3 2023.
- Average EBIAT over 5 years is -$11.1 million, with a median of -$10.0 million recorded in 2022.
- Peak YoY movement for EBIAT: tumbled 29981.93% in 2023, then soared 101.19% in 2025.
- A 5-year view of EBIAT shows it stood at -$9.5 million in 2021, then surged by 37.82% to -$5.9 million in 2022, then crashed by 314.94% to -$24.6 million in 2023, then skyrocketed by 34.18% to -$16.2 million in 2024, then surged by 50.17% to -$8.1 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$8.1 million in Q4 2025, -$274000.0 in Q3 2025, and $204000.0 in Q2 2025.